Alpine Woods Capital Investors LLC Raises Holdings in Kenvue Inc. (NYSE:KVUE)

Alpine Woods Capital Investors LLC boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 14.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 308,165 shares of the company’s stock after acquiring an additional 39,199 shares during the quarter. Kenvue accounts for about 1.2% of Alpine Woods Capital Investors LLC’s investment portfolio, making the stock its 21st largest holding. Alpine Woods Capital Investors LLC’s holdings in Kenvue were worth $6,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Grove Bank & Trust raised its position in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Kenvue during the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its position in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in Kenvue during the 3rd quarter valued at approximately $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.5 %

KVUE stock opened at $23.20 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.33 billion, a PE ratio of 43.76, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The business has a 50 day moving average of $21.81 and a 200 day moving average of $22.37.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent analyst reports. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.